{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-031053","form_type":"8-K","ticker":"FHTX","cik":"0001822462","company_name":"Foghorn Therapeutics Inc.","filed_at":"2023-08-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.455590+00:00","generated_at":"2026-06-11T01:24:56.809020+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Foghorn doses first patient in Phase 1 combo study of FHD-286 for AML","bullets":["FHD-286 in combination with decitabine or cytarabine for relapsed/refractory AML; first patient dosed.","Data from the Phase 1 combo study expected in second half of 2024.","Prior monotherapy study showed blast reductions and ANC recovery across genomic backgrounds.","Preclinical models with decitabine/cytarabine improved survival vs. single-agent controls.","Study uses 3+3 dose escalation to assess safety, tolerability, and efficacy."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-031053","json":"https://secwatch.observer/filing/0001628280-23-031053.json","markdown":"https://secwatch.observer/filing/0001628280-23-031053.md","text":"https://secwatch.observer/filing/0001628280-23-031053.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1822462/000162828023031053/0001628280-23-031053-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1822462/000162828023031053/fhtx-20230831.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T01:24:56.809020+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}